STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
The FDA approved a new breast cancer drug from Roche, teeing up the launch of a medicine the company has said could become its top-selling product ever.
STAT PlusPharma FDA approves new breast cancer drug, providing new option for some patients, boost for Roche Company believes therapy could become its top-selling product, though estimates vary Manage alerts for this article Save this story for later Share this article By Andrew JosephNov. 16, 2026 Europe Correspondent Andrew Joseph[email protected]Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
The Food and Drug Administration on Monday approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the Swiss company has said could become its top-selling product ever. The approval of Wilserdly, also known as giredestrant, was one of the most important regulatory decisions Roche had been awaiting. It also gives the company another foothold in breast cancer treatments, a field in which it has a storied history with the drug Herceptin through its subsidiary Genentech, though in recent years it’s fallen behind rival pharma companies in oncology.
Advertisement The approval is specifically for patients with HR-positive, HER2-negative advanced breast cancer that has picked up a mutation in the ESR1 gene, a sign that the tumor is developing resistance to standard treatments. The evERA trial showed that the drug, an oral treatment known as a selective estrogen receptor degrader, or SERD, extended the time period before patients’ tumors progressed. STAT+ Exclusive Story Already have an account?
Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!
Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, Pharmaceuticals, STAT+ Submit a correction requestReprints Andrew Joseph Europe Correspondent Andrew covers the biopharma industry, scientific research, and public health across the continent.
You can reach Andrew confidentially on Signal at drewqjoseph.71. STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Recommended In the Lab November 16, 2026 STAT Plus: Federal judge issues final ruling blocking U.S. plan to limit visa length for grad students, postdocs Pharma November 16, 2026 STAT Plus: In a win for MAHA, FDA creates new regulatory category for the supplement NAC Advertisement Pharmalot November 16, 2026 STAT Plus: Expert warns of battleground over global access to newer GLP-1 drugs for obesity Politics November 16, 2026 STAT Plus: NIAID acting head John Powers III appointed as the permanent director The Readout November 16, 2026 STAT Plus: Biotech’s rebound isn’t lifting all boats equally Subscriber Picks
comments(0)
5-min edit window · permanent after that